A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.

NCT Number	NCT07318155
Lead Sponsor	Sirius Therapeutics Co., Ltd.
Conditions	Coronary Artery Disease (CAD), Peripheral Arterial Disease
Enrollment	104 participants
Start Date	2025-03-11
Primary Completion	2027-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-29